Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Palatin Technologies Presents Compelling Preclinical Data on Next-Generation MC4R-Selective Peptide Agonists at ObesityWeek® 2026

      Palatin Technologies, Inc.

      News provided by

      Palatin Technologies, Inc.

      Nov 16, 2026, 07:30 ET

      Share this article

      Share this article


      • Novel peptide and long-acting lipidated peptide agonists demonstrate potent MC4R activity with minimal to no MC1R activity, supporting the potential to substantially reduce or eliminate hyperpigmentation
      • Significant reductions in body weight and food intake demonstrated in preclinical models, with encouraging preliminary cardiovascular finding
      • Proprietary lipidation technology supports once-weekly or potentially less frequent dosing; lead candidate PL2001 advancing toward first-in-human studies in the first half of 2027

      PRINCETON, N.J., Nov. 16, 2026 /PRNewswire/ -- Palatin Technologies, Inc. (Nasdaq: PTN), a biopharmaceutical company developing differentiated, next-generation melanocortin receptor agonists, today announced the presentation of new preclinical data highlighting the Company's proprietary MC4R-selective peptide agonist programs at ObesityWeek® 2026, being held November 14–17 in Washington, D.C.

      The findings demonstrate potent and highly selective MC4R agonist activity, significant reductions in body weight and food intake in preclinical models, and extended drug exposure through Palatin's proprietary peptide lipidation technology. Importantly, the compounds demonstrated minimal to no MC1R activity in vitro, supporting Palatin's objective of substantially reducing or potentially eliminating hyperpigmentation, a recognized limitation of currently approved MC4R therapies.

      The data further support Palatin's development strategy focused on delivering potentially best-in-class MC4R agonists for rare neuroendocrine obesity disorders, including hypothalamic obesity (HO), Prader-Willi syndrome (PWS), and Bardet-Biedl syndrome (BBS).

      "These findings represent an important advancement in our next-generation MC4R development programs and reinforce our confidence in our ability to deliver highly differentiated therapies," said Carl Spana, Ph.D., President and Chief Executive Officer of Palatin. "We have demonstrated that potent MC4R agonism and meaningful preclinical weight-loss activity can be achieved with minimal to no MC1R activity, substantially reducing or eliminating hyperpigmentation, while our proprietary lipidation technology provides the potential for once-weekly or less frequent dosing. Combined with encouraging preliminary cardiovascular findings, these results directly address several of the most important limitations of existing MC4R therapies."

      Dr. Spana continued, "We believe that long-term efficacy, tolerability, and convenience will ultimately define the next generation of MC4R therapies. Our objective is not simply to replicate the benefits of existing treatments, but to meaningfully improve upon them. With PL2001 selected as a clinical development candidate and first-in-human studies targeted for the first half of 2027, we are increasingly confident in our ability to translate our differentiated preclinical science into potentially best-in-class treatments for patients with rare neuroendocrine obesity disorders."

      Key Preclinical Findings Presented at ObesityWeek® 2026

      Potent and highly selective MC4R agonist activity

      • Palatin's novel cyclic peptide (PL1000 series) and long-acting lipidated peptide (PL2000 series) compounds demonstrated potent activity at MC4R with minimal to no functional activity at MC1R in vitro.
      • The compounds demonstrated greater than 100-fold to greater than 200-fold selectivity for MC4R over MC1R in the reported functional assays.
      • This receptor selectivity supports the potential to substantially reduce or eliminate MC1R-mediated hyperpigmentation, a recognized adverse effect of approved MC4R agonist therapy.

      Significant pre-clinical weight-loss efficacy

      • Both selective cyclic peptides and long-acting lipidated peptides demonstrated significant reductions in body weight and food intake in diet-induced obese (DIO) mice.
      • The selective peptide PL1002 demonstrated significant, dose-dependent reductions in body weight and food intake following twice-daily administration.
      • A single subcutaneous dose of the lipidated peptide PL2001 demonstrated significant, dose-dependent reductions in body weight and food intake, supporting its long-acting pharmacologic profile.

      Proprietary lipidation technology supports extended duration of action

      • Palatin's proprietary lipidation approach substantially extended peptide exposure while maintaining MC4R potency and selectivity.
      • Preclinical pharmacokinetic studies demonstrated an approximately 24-hour half-life for lipidated peptides in rodents and greater than 168 hours in dogs, compared with approximately two hours for non-lipidated selective peptides.
      • These findings support the potential for once-weekly or less frequent subcutaneous administration, representing a more convenient treatment approach compared with currently approved once-daily injectable MC4R peptide therapy.

      Encouraging preliminary cardiovascular findings

      • The selective peptide PL1001 demonstrated no observed effects on heart rate or blood pressure at the efficacious doses and time points evaluated in preclinical studies.
      • Additional cardiovascular safety studies are planned to further characterize the therapeutic profile of Palatin's MC4R-selective compounds.

      Advancing Toward Clinical Development
      Palatin has selected PL2001, a novel long-acting, lipidated, MC4R-selective peptide agonist, as a clinical development candidate. IND-enabling and chemistry, manufacturing, and controls (CMC) activities are progressing, with first-in-human studies targeted for the first half of calendar 2027 and initial clinical data anticipated in the second half of 2027.

      In addition to its long-acting injectable peptide programs, Palatin continues to advance the development of orally administered MC4R-selective peptides. The Company's proprietary peptide chemistry and lipidation technology provide additional opportunities to develop compounds with improved stability and the potential for oral delivery.

      Together with Palatin's complementary oral small-molecule MC4R agonist program, these development efforts provide multiple approaches to achieving the Company's objective of delivering highly differentiated, potentially best-in-class MC4R therapies.

      ObesityWeek® 2026 Poster Presentation

      Title: In Vitro and Preclinical Characterization of Novel Selective Melanocortin-4 Receptor Agonists
      Presenter: Luipa Khandker, Ph.D.
      Conference: ObesityWeek® 2026, November 14–17, 2026, Washington, D.C.
      Poster Presentation Schedule: Saturday, November 14: 7:30–8:30 p.m. ET

      About ObesityWeek®
      ObesityWeek® is an annual international conference for obesity researchers and clinicians hosted by The Obesity Society. The conference presents developments in evidence-based obesity science, research, treatment, prevention, advocacy, and public policy. Held annually in various U.S. locations, ObesityWeek attracts over 3,200 attendees and features over 100 sessions, including lectures and presentations of scientific abstracts.

      About Melanocortin-4 Receptor Agonists Effect on Obesity
      Hypothalamic neurons expressing the melanocortin-4 receptor ("MC4R") play a central role in regulating stored energy, food intake and body weight. When MC4R pathway signaling is impaired, patients can experience severe hunger, reduced energy expenditure and early-onset or severe obesity. MC4R agonism represents a clinically validated therapeutic approach for obesity disorders driven by dysfunction of the melanocortin pathway.

      About Palatin Technologies, Inc.
      Palatin Technologies, Inc. is a biopharmaceutical company developing medicines targeting the melanocortin receptor system. Palatin's principal strategic development focus is advancing next-generation MC4R-selective agonists for rare neuroendocrine obesity disorders, including hypothalamic obesity, Prader-Willi syndrome and Bardet-Biedl syndrome. The Company is developing long-acting injectable peptide agonists, oral small-molecule agonists and an oral peptide agonist approach, with the objective of delivering differentiated efficacy, tolerability and dosing profiles suitable for long-term treatment. Palatin also utilizes collaborations, licensing arrangements and strategic partnerships to advance other melanocortin-based programs. For more information, visit www.palatin.com.

      Forward-Looking Statements
      This press release contains forward-looking statements within the meaning of applicable federal securities laws, including statements regarding the potential efficacy, selectivity, safety, tolerability, dosing convenience, and clinical benefits of Palatin's MC4R agonist programs; the potential to reduce or eliminate hyperpigmentation; the development of orally administered peptides; the timing of IND-enabling activities, regulatory submissions, clinical studies, and anticipated clinical data; and the potential development of best-in-class therapies. These statements are based on current expectations and assumptions and involve substantial risks and uncertainties. Preclinical findings may not predict clinical outcomes. Actual results may differ materially from those expressed or implied, including as a result of risks related to drug development, regulatory approvals, clinical trial outcomes, funding requirements, and other factors described in Palatin's filings with the Securities and Exchange Commission. Palatin undertakes no obligation to update forward-looking statements except as required by law.

      SOURCE Palatin Technologies, Inc.

      Modal title

      Also from this source

      Palatin to Report First Quarter Fiscal Year 2027 Results

      Palatin to Report First Quarter Fiscal Year 2027 Results

      Palatin Technologies, Inc. (Nasdaq: PTN) will announce its first quarter fiscal year 2027 operating results on Tuesday, November 17, 2026, before the ...

      Palatin Reports Fiscal Year 2026 Financial Results and Provides Business Update

      Palatin Reports Fiscal Year 2026 Financial Results and Provides Business Update

      Palatin Technologies, Inc. (Nasdaq: PTN), a biopharmaceutical company developing medicines that target the melanocortin receptor ("MCR") system,...

      More Releases From This Source

      Explore

      Biotechnology

      Biotechnology

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      Pharmaceuticals

      Pharmaceuticals

      Health Care & Hospitals

      Health Care & Hospitals

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.